Blog

AHFS Patient Medication Information Update – June 2017

The June update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of the update include:

New PMI Monographs

  • Ocrelizumab Injection (Ocrevus®)
    • Ocrelizumab injection is used to treat adults with relapsing-remitting forms (course of disease where symptoms flare up from time to time) or primary-progressive forms (symptoms gradually become worse over time) of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control).
  • Valbenazine (Ingrezza®)
    • Valbenazine is used to treat tardive dyskinesia (uncontrollable movement of the face, tongue, or other body parts).
  • Deutetrabenazine (Austedo®)
    • Deutetrabenazine is used to treat chorea (sudden movements that you cannot control) caused by Huntington’s disease (an inherited disease that causes the progressive breakdown of nerve cells in the brain).
  • Safinamide (Xadago®)
    • Safinamide is used along with the combination of levodopa and carbidopa (Duopa, Rytary, Sinemet, others) to treat “off” episodes (times of difficulty moving, walking, and speaking that may happen as medication wears off or at random) in people with Parkinson’s disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance).
  • Deflazacort (Emflaza®)
    • Deflazacort is used to treat Duchenne muscular dystrophy (DMD; a progressive disease in which the muscles do not function properly) in adults and children 5 years of age and older.
  • Dupilumab Injection (Dupixent®)
    • Dupilumab injection is used to treat the symptoms of eczema (atopic dermatitis; a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes) in people who cannot use other medications for their condition or whose eczema has not responded to other medications.
  • Plecanatide (Trulance®)
    • Plecanatide is used in adults to treat chronic idiopathic constipation (CIC; difficult or infrequent passage of stools that lasts for 3 months or longer and is not caused by a disease or a medication).
  • Crisaborole Topical (Eucrisa®)
    • Crisaborole is used to treat eczema (atopic dermatitis; a skin condition which causes the skin to be dry and itchy and to sometimes develop red, scaly rashes).
  • Oxymetazoline Topical (Rhofade®)
    • Oxymetazoline is used to treat ongoing facial redness caused by rosacea (a skin disease that causes redness and pimples on the face).

FDA MedWatch Alert Revisions

  • FDA is requiring new warnings, including the most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk.
    • Based on new data from two large clinical trials, the FDA has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations.
    • Affected Monographs:
      • Canagliflozin